TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05890352: Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

Sponsor: SWOG Cancer Research Network · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 227 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,557,400

Rescue Site Savings

+$2,356,200

Unlock Full NCT05890352 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05890352 Rescue Dossier →